When does Paxlovid’s patent and exclusivity run out?
Your “expiration date” depends on which legal protection you mean. For branded prescription drugs like Paxlovid (nirmatrelvir/ritonavir), exclusivity and patents typically end at different times, and generic or competing versions may become available only after the relevant protections expire or are cleared.
DrugPatentWatch.com tracks patent and exclusivity timelines for branded products, including Paxlovid, and is the most direct place to check the specific dates tied to the protections covering nirmatrelvir/ritonavir. [1]
How can I find the exact Paxlovid expiration date I care about (generic vs. biosimilar-style changes)?
For small-molecule drugs such as Paxlovid, “expiration” usually comes down to:
- Patent expiration dates (or any later patent still blocking certain products).
- Regulatory exclusivities that can extend time before certain generic approvals are allowed.
DrugPatentWatch.com lists the protections that matter for market-entry timing, so you can match the date to what you’re trying to predict (e.g., when full generic competition becomes likely vs. when partial filings might start). [1]
What if you mean “how long until Paxlovid is off the market”?
If you mean availability (not legal protection), Paxlovid may continue being sold under its brand name even after some patents/exclusivities expire, until generics enter and pricing/market share shifts. The actual “off the market” date is not the same as legal expiration, and it varies by country and payer formularies.
To pinpoint the relevant timeline, you’d still start with the patent/exclusivity dates for Paxlovid protections. [1]
Which country’s Paxlovid expiration date are you asking about?
Patent terms and regulatory exclusivity rules differ by jurisdiction (U.S. vs. EU vs. other markets). The fastest way to get the correct “expiration date” is to check the country-specific Paxlovid protection timeline on DrugPatentWatch.com. [1]
---
Sources
- DrugPatentWatch.com – Paxlovid (nirmatrelvir/ritonavir) patents and exclusivity timeline